Which has preferable earnings and valuation, ELVN or SLDB?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Solid Biosciences N/A N/A -$174.32M -$1.91 N/A

Is ELVN or SLDB more profitable?

Enliven Therapeutics' return on equity of -18.55% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -18.55% -18.09% Solid Biosciences N/A -71.35% -60.58%

Does the media favor ELVN or SLDB?

In the previous week, Enliven Therapeutics had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 6 mentions for Enliven Therapeutics and 4 mentions for Solid Biosciences. Enliven Therapeutics' average media sentiment score of 1.66 beat Solid Biosciences' score of 0.91 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LEGN or SLDB?

In the previous week, Legend Biotech had 4 more articles in the media than Solid Biosciences. MarketBeat recorded 8 mentions for Legend Biotech and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.91 beat Legend Biotech's score of 0.74 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLAY or SLDB more profitable?

Relay Therapeutics' return on equity of -42.27% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Relay Therapeutics N/A -42.27% -38.67% Solid Biosciences N/A -71.35% -60.58%

Does the media prefer RLAY or SLDB?

In the previous week, Relay Therapeutics had 11 more articles in the media than Solid Biosciences. MarketBeat recorded 15 mentions for Relay Therapeutics and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.91 beat Relay Therapeutics' score of 0.89 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, VKTX or SLDB?

Viking Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A Solid Biosciences N/A N/A -$174.32M -$1.91 N/A

Is VKTX or SLDB more profitable?

Solid Biosciences' return on equity of -71.35% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Viking Therapeutics N/A -94.56% -82.75% Solid Biosciences N/A -71.35% -60.58%

Does the media refer more to VKTX or SLDB?

In the previous week, Viking Therapeutics had 6 more articles in the media than Solid Biosciences. MarketBeat recorded 10 mentions for Viking Therapeutics and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.91 beat Viking Therapeutics' score of 0.73 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IOVA or SLDB?

In the previous week, Solid Biosciences had 1 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 3 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.75 beat Solid Biosciences' score of 0.91 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Solid Biosciences (SLDB) Competitors

$8.70 -0.37 (-4.08%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$8.96 +0.26 (+2.99%)

As of 09/11/2026 07:59 PM Eastern

Compare

SLDB vs. ELVN, LEGN, RLAY, VKTX, and IOVA

Should you buy Solid Biosciences stock or one of its competitors? Solid Biosciences's main competitors and comparable companies include Enliven Therapeutics (ELVN), Legend Biotech (LEGN), Relay Therapeutics (RLAY), Viking Therapeutics (VKTX), and Iovance Biotherapeutics (IOVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Solid Biosciences compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 2.7% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Enliven Therapeutics had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 6 mentions for Enliven Therapeutics and 4 mentions for Solid Biosciences. Enliven Therapeutics' average media sentiment score of 1.66 beat Solid Biosciences' score of 0.91 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics presently has a consensus target price of $75.00, indicating a potential upside of 38.07%. Solid Biosciences has a consensus target price of $18.18, indicating a potential upside of 108.99%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Solid Biosciences is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Enliven Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market.

Enliven Therapeutics' return on equity of -18.55% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-18.55%	-18.09%
Solid Biosciences	N/A	-71.35%	-60.58%

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

Summary

Enliven Therapeutics beats Solid Biosciences on 8 of the 13 factors compared between the two stocks.

How does Solid Biosciences compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Solid Biosciences has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.51	-$296.80M	-$0.25	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

Legend Biotech currently has a consensus price target of $53.14, indicating a potential upside of 185.10%. Solid Biosciences has a consensus price target of $18.18, indicating a potential upside of 108.99%. Given Legend Biotech's higher probable upside, equities analysts plainly believe Legend Biotech is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Legend Biotech had 4 more articles in the media than Solid Biosciences. MarketBeat recorded 8 mentions for Legend Biotech and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.91 beat Legend Biotech's score of 0.74 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Legend Biotech has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Solid Biosciences	N/A	-71.35%	-60.58%

Summary

Solid Biosciences beats Legend Biotech on 9 of the 15 factors compared between the two stocks.

How does Solid Biosciences compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Relay Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market.

Relay Therapeutics currently has a consensus price target of $25.92, suggesting a potential upside of 37.34%. Solid Biosciences has a consensus price target of $18.18, suggesting a potential upside of 108.99%. Given Solid Biosciences' higher probable upside, analysts clearly believe Solid Biosciences is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Solid Biosciences has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	269.39	-$276.48M	-$1.57	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

In the previous week, Relay Therapeutics had 11 more articles in the media than Solid Biosciences. MarketBeat recorded 15 mentions for Relay Therapeutics and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.91 beat Relay Therapeutics' score of 0.89 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Relay Therapeutics' return on equity of -42.27% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-42.27%	-38.67%
Solid Biosciences	N/A	-71.35%	-60.58%

Summary

Relay Therapeutics beats Solid Biosciences on 9 of the 15 factors compared between the two stocks.

How does Solid Biosciences compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Viking Therapeutics currently has a consensus target price of $96.63, indicating a potential upside of 202.14%. Solid Biosciences has a consensus target price of $18.18, indicating a potential upside of 108.99%. Given Viking Therapeutics' higher probable upside, equities analysts clearly believe Viking Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Solid Biosciences' return on equity of -71.35% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
Solid Biosciences	N/A	-71.35%	-60.58%

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Viking Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

Viking Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market.

In the previous week, Viking Therapeutics had 6 more articles in the media than Solid Biosciences. MarketBeat recorded 10 mentions for Viking Therapeutics and 4 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.91 beat Viking Therapeutics' score of 0.73 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Solid Biosciences beats Viking Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Solid Biosciences compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Solid Biosciences has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -89.11%. Iovance Biotherapeutics' return on equity of -40.51% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-89.11%	-40.51%	-31.65%
Solid Biosciences	N/A	-71.35%	-60.58%

Iovance Biotherapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market.

Iovance Biotherapeutics currently has a consensus price target of $8.89, suggesting a potential upside of 3.36%. Solid Biosciences has a consensus price target of $18.18, suggesting a potential upside of 108.99%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Solid Biosciences is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Solid Biosciences has lower revenue, but higher earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	14.78	-$390.98M	-$0.73	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

In the previous week, Solid Biosciences had 1 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 3 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 1.75 beat Solid Biosciences' score of 0.91 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Solid Biosciences beats Iovance Biotherapeutics on 9 of the 15 factors compared between the two stocks.

Get Solid Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLDB vs. The Competition

Export

Metric	Solid Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$932.86M	$3.86B	$7.17B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-4.55	14.18	274.94	25.33
Price / Sales	N/A	1,375.01	685.45	111.12
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	3.82	15.12	10.33	6.20
Net Income	-$174.32M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-15.12%	-4.34%	-3.32%	-2.35%
1 Month Performance	-3.97%	-0.02%	-0.41%	-2.77%
1 Year Performance	61.41%	40.64%	19.21%	7.63%

Solid Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLDB Solid Biosciences	2.0273 of 5 stars	$8.70 -4.1%	$18.18 +109.0%	+61.4%	$932.86M	N/A	N/A	100	News Coverage Gap Down
ELVN Enliven Therapeutics	2.5767 of 5 stars	$59.65 +1.1%	$75.00 +25.7%	+172.1%	$4.32B	N/A	N/A	50	Positive News
LEGN Legend Biotech	3.517 of 5 stars	$21.75 -0.6%	$52.29 +140.4%	-43.7%	$4.24B	$1.03B	N/A	2,965	News Coverage Analyst Forecast
RLAY Relay Therapeutics	2.3413 of 5 stars	$19.01 +2.7%	$25.92 +36.3%	+372.9%	$4.06B	$15.35M	N/A	330	Insider Trade
VKTX Viking Therapeutics	2.9156 of 5 stars	$33.98 +1.4%	$96.63 +184.4%	+28.9%	$3.91B	N/A	N/A	20	News Coverage Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLDB) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solid Biosciences (SLDB) Competitors

SLDB vs. ELVN, LEGN, RLAY, VKTX, and IOVA

How does Solid Biosciences compare to Enliven Therapeutics?

Summary

How does Solid Biosciences compare to Legend Biotech?

Summary

How does Solid Biosciences compare to Relay Therapeutics?

Summary

How does Solid Biosciences compare to Viking Therapeutics?

Summary

How does Solid Biosciences compare to Iovance Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solid Biosciences (SLDB) Competitors

SLDB vs. ELVN, LEGN, RLAY, VKTX, and IOVA

How does Solid Biosciences compare to Enliven Therapeutics?

Do insiders & institutionals have more ownership in ELVN or SLDB?

Does the media favor ELVN or SLDB?

Do analysts prefer ELVN or SLDB?

Which has more risk and volatility, ELVN or SLDB?

Is ELVN or SLDB more profitable?

Which has preferable earnings and valuation, ELVN or SLDB?

Summary

How does Solid Biosciences compare to Legend Biotech?

Which has stronger valuation and earnings, LEGN or SLDB?

Do analysts prefer LEGN or SLDB?

Does the media favor LEGN or SLDB?

Do institutionals and insiders have more ownership in LEGN or SLDB?

Which has more volatility and risk, LEGN or SLDB?

Is LEGN or SLDB more profitable?

Summary

How does Solid Biosciences compare to Relay Therapeutics?

Which has more volatility and risk, RLAY or SLDB?

Do analysts recommend RLAY or SLDB?

Which has better earnings & valuation, RLAY or SLDB?

Does the media prefer RLAY or SLDB?

Do insiders & institutionals hold more shares of RLAY or SLDB?

Is RLAY or SLDB more profitable?

Summary

How does Solid Biosciences compare to Viking Therapeutics?

Do analysts rate VKTX or SLDB?

Is VKTX or SLDB more profitable?

Do institutionals & insiders have more ownership in VKTX or SLDB?

Which has better earnings & valuation, VKTX or SLDB?

Which has more risk & volatility, VKTX or SLDB?

Does the media refer more to VKTX or SLDB?

Summary

How does Solid Biosciences compare to Iovance Biotherapeutics?

Do insiders and institutionals hold more shares of IOVA or SLDB?

Is IOVA or SLDB more profitable?

Which has more volatility & risk, IOVA or SLDB?

Do analysts prefer IOVA or SLDB?

Which has higher valuation & earnings, IOVA or SLDB?

Does the media favor IOVA or SLDB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB vs. The Competition

Solid Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools